Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
4.8
Journals
Pharmaceuticals
Special Issues
Advances in Drug Treatment for Pediatric Gastroenterology
share announcement

Advances in Drug Treatment for Pediatric Gastroenterology

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: closed (25 January 2026) | Viewed by 1512

Special Issue Editors

Dr. Roxana Elena Matran

E-Mail Website
Guest Editor
1. Department of Paediatrics, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
2. “Grigore Alexandrescu” Emergency Hospital for Children, 011743 Bucharest, Romania
Interests: inflammatory bowel disease; clinical nutrition; biologics
Dr. Iulia Florentina Ţincu

E-Mail Website
Guest Editor
1. Department of Paediatrics, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
2. “Dr. Victor Gomoiu” Clinical Children Hospital, Bucharest, Romania
Interests: biologics; eosinophilic esophagitis; inflammatory bowel disease; clinical nutrition
Dr. Corina Pienar

E-Mail Website
Guest Editor
Department of Pediatrics, 2nd Pediatrics Clinic, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
Interests: pediatrics; gastrointestinal disease; cow’s milk protein allergy; abdominal ultrasound
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The field of pediatric gastroenterology is rapidly evolving, characterized by the introduction of novel biologic agents, enzyme replacement therapies, microbiome-targeted interventions, and the integration of precision medicine, leading to improved patient outcomes and quality of life. This is complemented by substantial progress in diagnostic modalities, nutritional strategies, and the adoption of multidisciplinary individualized treatments.

Therefore, this Special Issue seeks to provide a comprehensive platform for the dissemination of innovative research, clinical experiences, and expert perspectives on the latest therapeutic approaches in pediatric gastroenterology.

We hope this Special Issue will be a reference source for clinicians and researchers, fostering the exchange of knowledge and best practices addressing the evolving challenges encountered in the treatment of pediatric gastrointestinal disorders.

We look forward to receiving your valuable contributions and showcasing the latest achievements in this evolving field.

Dr. Roxana Elena Matran
Dr. Iulia Florentina Ţincu
Dr. Corina Pienar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biologics
  • Crohn’s disease
  • ulcerative colitis
  • eosinophilic esophagitis
  • autoimmune hepatitis
  • probiotics
  • inflammatory bowel disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

27 pages, 741 KB  
Review
Advances in the Management of Pediatric Inflammatory Bowel Disease: From Biologics to Small Molecules
by Benedetta Mucci, Elisabetta Palazzolo, Flaminia Ruberti, Lorenzo Ientile, Marco Natale and Susanna Esposito
Pharmaceuticals 2026, 19(1), 176; https://doi.org/10.3390/ph19010176 - 20 Jan 2026
Viewed by 1056
Abstract
Background: The management of pediatric inflammatory bowel disease (PIBD) has evolved significantly over the past two decades, transitioning from corticosteroids and immunomodulators to biologic and small-molecule therapies. These advances have aimed not only to control inflammation but also to promote mucosal healing, improve [...] Read more.
Background: The management of pediatric inflammatory bowel disease (PIBD) has evolved significantly over the past two decades, transitioning from corticosteroids and immunomodulators to biologic and small-molecule therapies. These advances have aimed not only to control inflammation but also to promote mucosal healing, improve growth, and enhance long-term quality of life. Objectives: This narrative review summarizes current evidence on the efficacy, safety, and clinical applications of biologic and novel small-molecule therapies in PIBD, highlighting emerging trends in personalized and precision-based management. Methods: A literature search was performed across PubMed, Embase, and the Cochrane Library, focusing on studies published within the last five years. Additional data were retrieved from key guidelines and position papers issued by ECCO–ESPGHAN, SIGENP, the FDA, and the EMA. Results: Anti–tumor necrosis factor (TNF) agents such as infliximab and adalimumab remain first-line biologics with proven efficacy in remission induction and maintenance. Newer biologics—vedolizumab, ustekinumab, risankizumab, and mirikizumab—offer alternatives for anti-TNF-refractory cases, showing encouraging short-term results and favorable safety profiles. Although many are approved only for adults with limited pediatric evidence, emerging small molecules—including Janus kinase (JAK) inhibitors (tofacitinib, upadacitinib) and sphingosine-1-phosphate (S1P) modulators (etrasimod)—provide oral, rapidly acting, and non-immunogenic treatment options for refractory disease. Furthermore, the gut microbiome is increasingly recognized as an emerging therapeutic target in PIBD, with growing evidence that host–microbiome interactions can influence both the efficacy and safety of biologics and small-molecule therapies. Conclusions: While biologics and small molecules have transformed PIBD management, challenges remain, including high treatment costs, limited pediatric trial data, and variable access worldwide. Future directions include multicenter pediatric studies, integration of pharmacogenomics, and biomarker-guided precision medicine to optimize early, individualized treatment and improve long-term outcomes. Full article
(This article belongs to the Special Issue Advances in Drug Treatment for Pediatric Gastroenterology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop